Pharmaceuticals
3SBio announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development
HONG KONG, Aug. 26, 2021 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today unveiled its 2021 interim results. 3SBio maintained strong performance in core businesses, with core products occupying a leading market share. Meanwhile, the Company continuously increased ...
2021-08-26 22:09
6764
Modern Chinese Medicine Announces Year 2021 Interim Results
PERFORMANCE HIGHLIGHTS * Revenue increased by 8.8% to RMB171.8 million * Gross profit increased by 10.4% to RMB78.6 million * Profit after tax increased by 10.5% to approximately RMB44.1 million * The increase in revenue was primarily driven by the surge in revenue generated from the sales...
2021-08-26 20:46
5744
INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800
INOVIO's global Phase 3 efficacy trial receives authorization to proceed from Brazil; other countries to follow INOVIO to conduct INNOVATE Phase 3 efficacy trial with partner Advaccine in areas of world in need of COVID-19 vaccines PLYMOUTH MEETING, Pa., Aug. 26, 2021 /PRNewswire/ -- INOVIO (NAS...
2021-08-26 20:00
3938
RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights
TEL AVIV, Israel and RALEIGH, N.C., Aug. 26, 2021 /PRNewswire/ -- RedHill
Biopharma Ltd.
2021-08-26 19:56
7598
RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant
TEL AVIV, Israel and RALEIGH, N.C., Aug. 26, 2021 /PRNewswire/ -- RedHill
Biopharma Ltd.
2021-08-26 19:50
3934
CStone Pharmaceuticals Announces 2021 Interim Results
SUZHOU, China, Aug. 26, 2021 /PRNewswire/ -- CStone Pharmaceuticals (CStone, HKEX: 2616), a leading biopharmaceutical company focused on researching, developing and commercializing innovative immuno-oncology therapies and precision medicines, today announced 2021 financial results. "In the first...
2021-08-26 19:14
6259
First patient treated in Clarity's Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial
SYDNEY, Aug. 25, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or the "Company"), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, is pleased to announce that the first US patient has ...
2021-08-25 21:18
6533
Innovent Announced 2021 Interim Results with Total Revenue of RMB 1,941.8 Million and Accelerated Global R&D Footprint
SAN FRANCISCO and SUZHOU, China, Aug. 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2021-08-25 20:53
5865
Kintor Pharma Collaborates with Etana to Commercialize Proxalutamide for Treatment of COVID-19 in Indonesia
SUZHOU, China, Aug. 25, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that it has entered into a licensing agreement with PT Etana Biotechnol...
2021-08-25 19:25
4804
Senhwa Biosciences Announces Dose Escalation Initiation of the Phase I Trial of Pidnarulex as a Treatment for Advanced Hematological Malignancies
TAIPEI and SAN DIEGO, Aug. 25, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, today announced the initiation of Dose Escalation within the Phase I Investigator Init...
2021-08-25 19:00
2119
Moolec Science and Grupo Insud Launch Food-Tech Joint Venture
WARWICK, England, Aug. 25, 2021 /PRNewswire/ -- Moolec, a science-based ingredients company using plants to produce animal proteins, andGrupo Insud, a global conglomerate with a strong presence in the manufacturing of biosimilars and other active ingredients for the pharmaceutical industry, annou...
2021-08-25 18:00
1848
Extended Malaysian wound care tender: Bactiguard Holding
STOCKHOLM, Aug. 25, 2021 /PRNewswire/ -- Bactiguard's tender award for wound care products for the public sector inMalaysia has been extended by another year and the volume has increased. This enables healthcare providers in both primary and secondary care to purchase Bactiguard's Wound Care syst...
2021-08-25 15:49
1933
Ocumension Acquires all the Equity Interests in Two Ophthalmic Products Mainland China, Further Enhancing its Pipeline Strength
HONG KONG, Aug. 25, 2021 /PRNewswire/ -- Beijing time, August 24, 2021, Ocumension Therapeutics announced that it has entered into a product acquisition agreement with a leading global pharmaceutical company Novartis, pursuant to which the Company will acquire all the equity interests in two oph...
2021-08-25 12:35
4355
Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients
DURHAM, N.C. and BEIJING, Aug. 25, 2021 /PRNewswire/ -- Brii Biosciences
2021-08-25 08:42
3780
Ascletis Announces Completion of the Bridging Study and Initiation of Phase II Trial of FXR Agonist ASC42 in China for Chronic Hepatitis B Indication
HANGZHOU and SHAOXING, China, Aug. 25, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today the completion of the bridging study and initiation of Phase II trial of farnesoid X receptor (FXR) agonist ASC42 inChina for chronic hepatitis B (CHB) indication. ASC42 is an in-house de...
2021-08-25 08:30
4515
GenScript Biotech Reports First Half 2021 Results
* In the first half of 2021, the Group reported a revenue of approximately USD 229.6 million, a 38.0% YoY increase, and a gross profit of USD 138.6 million , achieving a 28.1% YoY growth. All four of the Group's business segments demonstrated steady growth. * Building on early strategic invest...
2021-08-24 21:38
6932
Ascentage Pharma Announces 2021 Interim Results Highlighting the Potential of Its Core Drug Candidates and Major Breakthroughs in Strategic Collaborations
SUZHOU, China, and ROCKVILLE, Md., Aug. 24, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its 2021 interim results and released an updat...
2021-08-24 19:06
3953
Kintor Pharma to Report 2021 Interim Financial Results and Host Conference Call on August 30, 2021
SUZHOU, China, Aug. 24, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today the company will review the interim results and business highlights on...
2021-08-24 17:04
2743
Alphamab Oncology and CSPC Achieved an Licensing Cooperation on Anti-HER2 Bispecific Antibody KN026 in Mainland China
SUZHOU, China, Aug. 24, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced today that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Jiangsu Alphamab" or "the Company"), a wholly-owned subsidiary of Alphamab Oncology, signed a contract with JMT-Bio, a wholly-owned subsidiary ...
2021-08-24 15:08
3317
China Medical System Holdings Limited 2021 Interim Results Announcement
Business Performance Reached Record High Turnover Increased by 23.6% to RMB3,843.0 Million Profit Increased by 25.5% to RMB1,631.6 Million Industrial Investment Enables Innovation Incubation New Businesses Boost Future Development Financial Highlights For the 6 months ended 30 June 2021 (RMB ...
2021-08-24 10:52
4441
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 308 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Hong Leong Bank Awarded Best Managed Bank in Malaysia by The Asian Banker, Group MD/CEO Kevin Lam Named Best Bank CEO in Malaysia
[Picked up by 293 media titles]
2026-05-15 17:00
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 290 media titles]
2026-05-18 15:30
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 280 media titles]
2026-05-20 09:15Most Read
H World Group Reports Q1 Results, Highlighting Asset-light Growth and Expanding APAC Footprint
2026-05-15 20:11
8077
